Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor (CAR) T-cell therapy; it is approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and represents a significant milestone in NHL drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient- and market-share leader in 2017 in the NHL space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DLBCL, and mantle cell lymphoma (MCL).
Population segments in market forecast: First line, second line, and third/fourth line for FL, CLL/SLL, DLBCL, and MCL.
Emerging therapies: Phase I and II: 45 drugs; Phase III: 10 drugs; registered: 5 drugs.
Already a Client? Log in to access this report.
Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.
Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.